cardioКардиологияKardiologiia0022-90402412-5660Kardiomag10.18087/cardio.n328cardio-328Research ArticleОБЗОРЫREVIEWSРенин-ангиотензин-альдостероновая система как потенциальная мишень для терапии пациентов с кальцинирующим аортальным стенозом: обзор литературыThe renin-angiotensin-aldosterone system as a potential target for therapy in patients with calcific aortic stenosis: a literature reviewhttps://orcid.org/0000-0001-6099-0315КостюнинА. Е.KostyuninA. E.

Sosnovy Bulvar 6, Kemerovo, 650002

ORCID: 0000-0001-6099-0315

Rhabdophis_tigrina@mail.ruhttps://orcid.org/0000-0001-7477-3979ОвчаренкоЕ. А.OvcharenkoE. A.

650002, Кемерово, Сосновый бульвар, 6

Sosnovy Bulvar 6, Kemerovo, 650002

ORCID: 0000-0001-7477-3979

ov.eugene@gmail.comhttps://orcid.org/0000-0002-4642-3610БарбарашО. Л.BarbarashO. L.

650002, Кемерово, Сосновый бульвар, 6

Sosnovy Bulvar 6, Kemerovo, 650002

ORCID: 0000-0002-4642-3610

olb61@mail.ruФГБНУ «Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний»РоссияResearch Institute for Complex Issues of Cardiovascular DiseasesRussian Federation2019120920195911S417Copyright © Kardiomag, 20192019KardiomagKardiomaghttps://cardio.elpub.ru/jour/about/submissions#copyrightNoticehttps://cardio.elpub.ru/jour/article/view/328

Calcific aortic valve stenosis (CAVS) is a serious socio-economic problem in developed countries because this disease is the most common indication for aortic valve replacement. Currently, there are no methods for non-invasive treatment of CAVS. Nevertheless, it is assumed that effective drug therapy for CAVS can be developed on the basis of modulators of the renin-angiotensin-aldosterone system (RAAS), which is involved in the pathogenesis of this disease. The purpose of this paper is to compile and analyze current information on the role of RAAS in the CAVS pathophysiology. Recent data on the effectiveness of RAAS inhibition are reviewed.

Аортальный стенозренин-ангиотензин-альдостероновая системакальцификацияпатофизиологияконсервативная терапияингибиторы АПФAortic stenosisrenin-angiotensin-aldosterone systemcalcificationpathophysiologyconservative treatmentACE inhibitorsРабота выполнена в рамках комплексной программы фундаментальных научных исследований СО РАН по фундаментальной теме НИИ КПССЗ № 0546-2015-0011 «Патогенетическое обоснование разработки имплантатов для сердечно-сосудистой хирургии на основе биосовместимых материалов, с реализацией пациент-ориентированного подхода с использованием математического моделирования, тканевой инженерии и геномных предикторов».ReferencesLindman BR, Clavel M-A, Mathieu P, Iung B, Lancellotti P, Otto CM et al. Calcific aortic stenosis. Nature Reviews Disease Primers. 2016;2(1):16006. DOI: 10.1038/nrdp.2016.6Lindman BR, Clavel M-A, Mathieu P, Iung B, Lancellotti P, Otto CM et al. Calcific aortic stenosis. Nature Reviews Disease Primers. 2016;2(1):16006. DOI: 10.1038/nrdp.2016.6Authors/Task Force Members, Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Barón-Esquivias G et al. Guidelines on the management of valvular heart disease (version 2012). European Heart Journal. 2012;33(19):2451–96. DOI: 10.1093/eurheartj/ehs109Authors/Task Force Members, Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Barón-Esquivias G et al. Guidelines on the management of valvular heart disease (version 2012). European Heart Journal. 2012;33(19):2451–96. DOI: 10.1093/eurheartj/ehs109d’Arcy JL, Prendergast BD, Chambers JB, Ray SG, Bridgewater B. Valvular heart disease: the next cardiac epidemic. Heart. 2011;97(2):91–3. DOI: 10.1136/hrt.2010.205096d’Arcy JL, Prendergast BD, Chambers JB, Ray SG, Bridgewater B. Valvular heart disease: the next cardiac epidemic. Heart. 2011;97(2):91–3. DOI: 10.1136/hrt.2010.205096Iung B, Vahanian A. Degenerative calcific aortic stenosis: a natural history. Heart. 2012;98(Suppl 4):iv7–13. DOI: 10.1136/heartjnl-2012-302395Iung B, Vahanian A. Degenerative calcific aortic stenosis: a natural history. Heart. 2012;98(Suppl 4):iv7–13. DOI: 10.1136/heartjnl-2012-302395Osnabrugge RLJ, Mylotte D, Head SJ, Van Mieghem NM, Nkomo VT, LeReun CM et al. Aortic Stenosis in the Elderly: disease prevalence and number of candidates for transcatheter aortic valve replacement: a meta-analysis and modeling study. Journal of the American College of Cardiology. 2013;62(11):1002–12. DOI: 10.1016/j.jacc.2013.05.015Osnabrugge RLJ, Mylotte D, Head SJ, Van Mieghem NM, Nkomo VT, LeReun CM et al. Aortic Stenosis in the Elderly: disease prevalence and number of candidates for transcatheter aortic valve replacement: a meta-analysis and modeling study. Journal of the American College of Cardiology. 2013;62(11):1002–12. DOI: 10.1016/j.jacc.2013.05.015Thaden JJ, Nkomo VT, Enriquez-Sarano M. The Global Burden of Aortic Stenosis. Progress in Cardiovascular Diseases. 2014;56(6):565–71. DOI: 10.1016/j.pcad.2014.02.006Thaden JJ, Nkomo VT, Enriquez-Sarano M. The Global Burden of Aortic Stenosis. Progress in Cardiovascular Diseases. 2014;56(6):565–71. DOI: 10.1016/j.pcad.2014.02.006Marquis-Gravel G, Redfors B, Leon MB, Généreux P. Medical Treatment of Aortic Stenosis. Circulation. 2016;134(22):1766–84. DOI: 10.1161/CIRCULATIONAHA.116.023997Marquis-Gravel G, Redfors B, Leon MB, Généreux P. Medical Treatment of Aortic Stenosis. Circulation. 2016;134(22):1766–84. DOI: 10.1161/CIRCULATIONAHA.116.023997Salas MJ, Santana O, Escolar E, Lamas GA. Medical Therapy for Calcific Aortic Stenosis. Journal of Cardiovascular Pharmacology and Therapeutics. 2012;17(2):133–8. DOI: 10.1177/1074248411416504Salas MJ, Santana O, Escolar E, Lamas GA. Medical Therapy for Calcific Aortic Stenosis. Journal of Cardiovascular Pharmacology and Therapeutics. 2012;17(2):133–8. DOI: 10.1177/1074248411416504Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. European Heart Journal. 2017;38(36):2739–91. DOI: 10.1093/eurheartj/ehx391Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. European Heart Journal. 2017;38(36):2739–91. DOI: 10.1093/eurheartj/ehx391Lindman BR, Bonow RO, Otto CM. Current Management of Calcific Aortic Stenosis. Circulation Research. 2013;113(2):223–37. DOI: 10.1161/CIRCRESAHA.111.300084Lindman BR, Bonow RO, Otto CM. Current Management of Calcific Aortic Stenosis. Circulation Research. 2013;113(2):223–37. DOI: 10.1161/CIRCRESAHA.111.300084Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Fleisher LA et al. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients with Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017;135(25):e1159–95. DOI: 10.1161/CIR.0000000000000503Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Fleisher LA et al. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients with Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017;135(25):e1159–95. DOI: 10.1161/CIR.0000000000000503Гуляев Н. И., Варавин Н. А., Коровин А. Е., Кузнецов В. В., Яковлев В. В., Гордиенко А. В. Современные аспекты патогенеза кальциноза аортальных полулуний (обзор литературы). Вестник СПбГУ. 2016;3:20-34. DOI: 10.21638/11701/spbu11.2016.302Gulyaev N.I., Varavin N.A., Korovin A.E., Kuznetsov V.V., Yakovlev V.V., Gordienko A.V. Modern aspects of pathogenesis of calcification of the aortic valve. Bulletin of Saint-Petersburg State University. 2016;3:20–34. DOI: 10.21638/11701/spbu11.2016.302Pacurari M, Kafoury R, Tchounwou PB, Ndebele K. The ReninAngiotensin-Aldosterone System in Vascular Inflammation and Remodeling. International Journal of Inflammation. 2014;2014:689360. DOI: 10.1155/2014/689360Pacurari M, Kafoury R, Tchounwou PB, Ndebele K. The ReninAngiotensin-Aldosterone System in Vascular Inflammation and Remodeling. International Journal of Inflammation. 2014;2014:689360. DOI: 10.1155/2014/689360Cao W, Hu N, Yuan Y, Cheng J, Guo X, Wang Y et al. Effects of Tilianin on Proliferation, Migration and TGF-β/Smad Signaling in Rat Vascular Smooth Muscle Cells Induced with Angiotensin II: Pharmacological effect of Talinin on rat vascular smooth muscle cells. Phytotherapy Research. 2017;31(8):1240–8. DOI: 10.1002/ptr.5846Cao W, Hu N, Yuan Y, Cheng J, Guo X, Wang Y et al. Effects of Tilianin on Proliferation, Migration and TGF-β/Smad Signaling in Rat Vascular Smooth Muscle Cells Induced with Angiotensin II: Pharmacological effect of Talinin on rat vascular smooth muscle cells. Phytotherapy Research. 2017;31(8):1240–8. DOI: 10.1002/ptr.5846Chen T, Li M, Fan X, Cheng J, Wang L. Sodium Tanshinone IIA Sulfonate Prevents Angiotensin II-Induced Differentiation of Human Atrial Fibroblasts into Myofibroblasts. Oxidative Medicine and Cellular Longevity. 2018;2018:6712585. DOI: 10.1155/2018/6712585Chen T, Li M, Fan X, Cheng J, Wang L. Sodium Tanshinone IIA Sulfonate Prevents Angiotensin II-Induced Differentiation of Human Atrial Fibroblasts into Myofibroblasts. Oxidative Medicine and Cellular Longevity. 2018;2018:6712585. DOI: 10.1155/2018/6712585Wu X, Liu Y, An J, Li J, Lv W, Geng S et al. Piperlongumine inhibits angiotensin II-induced extracellular matrix expression in cardiac fibroblasts. Journal of Cellular Biochemistry. 2018;119(12):10358–64. DOI: 10.1002/jcb.27379Wu X, Liu Y, An J, Li J, Lv W, Geng S et al. Piperlongumine inhibits angiotensin II-induced extracellular matrix expression in cardiac fibroblasts. Journal of Cellular Biochemistry. 2018;119(12):10358–64. DOI: 10.1002/jcb.27379Barhoumi T, Fraulob-Aquino JC, Mian MOR, Ouerd S, IdrisKhodja N, Huo K-G et al. Matrix metalloproteinase-2 knockout prevents angiotensin II-induced vascular injury. Cardiovascular Research. 2017;113(14):1753–62. DOI: 10.1093/cvr/cvx115Barhoumi T, Fraulob-Aquino JC, Mian MOR, Ouerd S, IdrisKhodja N, Huo K-G et al. Matrix metalloproteinase-2 knockout prevents angiotensin II-induced vascular injury. Cardiovascular Research. 2017;113(14):1753–62. DOI: 10.1093/cvr/cvx115Kong J, Zhang Y, Liu S, Li H, Liu S, Wang J et al. Melatonin attenuates angiotensin II-induced abdominal aortic aneurysm through the down-regulation of matrix metalloproteinases. Oncotarget. 2017;8(9):14283–93. DOI: 10.18632/oncotarget.15093Kong J, Zhang Y, Liu S, Li H, Liu S, Wang J et al. Melatonin attenuates angiotensin II-induced abdominal aortic aneurysm through the down-regulation of matrix metalloproteinases. Oncotarget. 2017;8(9):14283–93. DOI: 10.18632/oncotarget.15093Guo F, Chen X-L, Wang F, Liang X, Sun Y-X, Wang Y-J. Role of Angiotensin II Type 1 Receptor in Angiotensin II-Induced Cytokine Production in Macrophages. Journal of Interferon & Cytokine Research. 2011;31(4):351–61. DOI: 10.1089/jir.2010.0073Guo F, Chen X-L, Wang F, Liang X, Sun Y-X, Wang Y-J. Role of Angiotensin II Type 1 Receptor in Angiotensin II-Induced Cytokine Production in Macrophages. Journal of Interferon & Cytokine Research. 2011;31(4):351–61. DOI: 10.1089/jir.2010.0073Manuneedhi Cholan P, Cartland SP, Dang L, Rayner BS, Patel S, Thomas SR et al. TRAIL protects against endothelial dysfunction in vivo and inhibits angiotensin-II-induced oxidative stress in vascular endothelial cells in vitro. Free Radical Biology and Medicine. 2018;126:341–9. DOI: 10.1016/j.freeradbiomed.2018.08.031Manuneedhi Cholan P, Cartland SP, Dang L, Rayner BS, Patel S, Thomas SR et al. TRAIL protects against endothelial dysfunction in vivo and inhibits angiotensin-II-induced oxidative stress in vascular endothelial cells in vitro. Free Radical Biology and Medicine. 2018;126:341–9. DOI: 10.1016/j.freeradbiomed.2018.08.031Tian H, Yu D, Hu Y, Zhang P, Yang Y, Hu Q et al. Angiotensin II upregulates cyclophilin A by enhancing ROS production in rat cardiomyocytes. Molecular Medicine Reports. 2018;18(5):4349–55. DOI: 10.3892/mmr.2018.9448Tian H, Yu D, Hu Y, Zhang P, Yang Y, Hu Q et al. Angiotensin II upregulates cyclophilin A by enhancing ROS production in rat cardiomyocytes. Molecular Medicine Reports. 2018;18(5):4349–55. DOI: 10.3892/mmr.2018.9448Han C, Liu J, Liu X, Li M. Angiotensin II induces C-reactive protein expression through ERK1/2 and JNK signaling in human aortic endothelial cells. Atherosclerosis. 2010;212(1):206–12. DOI: 10.1016/j.atherosclerosis.2010.05.020Han C, Liu J, Liu X, Li M. Angiotensin II induces C-reactive protein expression through ERK1/2 and JNK signaling in human aortic endothelial cells. Atherosclerosis. 2010;212(1):206–12. DOI: 10.1016/j.atherosclerosis.2010.05.020Ruiz-Ortega M, Ruperez M, Lorenzo O, Esteban V, Blanco J, Mezzano S et al. Angiotensin II regulates the synthesis of proinflam matory cytokines and chemokines in the kidney. Kidney International. 2002;82:S12–22. DOI: 10.1046/j.1523-1755.62.s82.4.xRuiz-Ortega M, Ruperez M, Lorenzo O, Esteban V, Blanco J, Mezzano S et al. Angiotensin II regulates the synthesis of proinflam matory cytokines and chemokines in the kidney. Kidney International. 2002;82:S12–22. DOI: 10.1046/j.1523-1755.62.s82.4.xOsako MK, Nakagami H, Shimamura M, Koriyama H, Nakagami F, Shimizu H et al. Cross-Talk of Receptor Activator of Nuclear Factor-κB Ligand Signaling With Renin–Angiotensin System in Vascular Calcification. Arteriosclerosis, Thrombosis, and Vascular Biology. 2013;33(6):1287–96. DOI: 10.1161/ATVBAHA.112.301099Osako MK, Nakagami H, Shimamura M, Koriyama H, Nakagami F, Shimizu H et al. Cross-Talk of Receptor Activator of Nuclear Factor-κB Ligand Signaling With Renin–Angiotensin System in Vascular Calcification. Arteriosclerosis, Thrombosis, and Vascular Biology. 2013;33(6):1287–96. DOI: 10.1161/ATVBAHA.112.301099Pueyo ME, Gonzalez W, Nicoletti A, Savoie F, Arnal JF, Michel JB. Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-kappaB activation induced by intracellular oxidative stress. Arteriosclerosis, Thrombosis, and Vascular Biology. 2000;20(3):645–51. DOI: 10.1161/01.atv.20.3.645Pueyo ME, Gonzalez W, Nicoletti A, Savoie F, Arnal JF, Michel JB. Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-kappaB activation induced by intracellular oxidative stress. Arteriosclerosis, Thrombosis, and Vascular Biology. 2000;20(3):645–51. DOI: 10.1161/01.atv.20.3.645Oparil S, Acelajado MC, Bakris GL, Berlowitz DR, Cífková R, Dominiczak AF et al. Hypertension. Nature Reviews Disease Primers. 2018;4(1):18014. DOI: 10.1038/nrdp.2018.14Oparil S, Acelajado MC, Bakris GL, Berlowitz DR, Cífková R, Dominiczak AF et al. Hypertension. Nature Reviews Disease Primers. 2018;4(1):18014. DOI: 10.1038/nrdp.2018.14Montecucco F, Pende A, Mach F. The Renin-Angiotensin System Modulates Inflammatory Processes in Atherosclerosis: Evidence from Basic Research and Clinical Studies. Mediators of Inflammation. 2009; 2009:752406. DOI: 10.1155/2009/752406Montecucco F, Pende A, Mach F. The Renin-Angiotensin System Modulates Inflammatory Processes in Atherosclerosis: Evidence from Basic Research and Clinical Studies. Mediators of Inflammation. 2009; 2009:752406. DOI: 10.1155/2009/752406Sata M, Fukuda D. Crucial role of renin-angiotensin system in the pathogenesis of atherosclerosis. The Journal of Medical Investigation. 2010;57(1–2):12–25. DOI: 10.2152/jmi.57.12Sata M, Fukuda D. Crucial role of renin-angiotensin system in the pathogenesis of atherosclerosis. The Journal of Medical Investigation. 2010;57(1–2):12–25. DOI: 10.2152/jmi.57.12George AJ, Thomas WG, Hannan RD. The renin–angiotensin system and cancer: old dog, new tricks. Nature Reviews Cancer. 2010;10(11):745–59. DOI: 10.1038/nrc2945George AJ, Thomas WG, Hannan RD. The renin–angiotensin system and cancer: old dog, new tricks. Nature Reviews Cancer. 2010;10(11):745–59. DOI: 10.1038/nrc2945Ishikane S, Takahashi-Yanaga F. The role of angiotensin II in cancer metastasis: Potential of renin-angiotensin system blockade as a treatment for cancer metastasis. Biochemical Pharmacology. 2018; 151:96–103. DOI: 10.1016/j.bcp.2018.03.008Ishikane S, Takahashi-Yanaga F. The role of angiotensin II in cancer metastasis: Potential of renin-angiotensin system blockade as a treatment for cancer metastasis. Biochemical Pharmacology. 2018; 151:96–103. DOI: 10.1016/j.bcp.2018.03.008Chu KY, Leung PS. Angiotensin II in type 2 diabetes mellitus. Current Protein & Peptide Science. 2009;10(1):75–84. DOI: 10.2174/138920309787315176Chu KY, Leung PS. Angiotensin II in type 2 diabetes mellitus. Current Protein & Peptide Science. 2009;10(1):75–84. DOI: 10.2174/138920309787315176Ribeiro-Oliveira AJr, Nogueira AI, Pereira RM, Boas WW, Dos Santos RA, Simões e Silva AC. The renin-angiotensin system and diabetes: An update. Vascular Health and Risk Management. 2008;4(4):787–803. DOI: 10.2147/VHRM.S1905Ribeiro-Oliveira AJr, Nogueira AI, Pereira RM, Boas WW, Dos Santos RA, Simões e Silva AC. The renin-angiotensin system and diabetes: An update. Vascular Health and Risk Management. 2008;4(4):787–803. DOI: 10.2147/VHRM.S1905Remuzzi G, Perico N, Macia M, Ruggenenti P. The role of reninangiotensin-aldosterone system in the progression of chronic kidney disease. Kidney International. 2005;99:S57–65. DOI: 10.1111/j.1523-1755.2005.09911.xRemuzzi G, Perico N, Macia M, Ruggenenti P. The role of reninangiotensin-aldosterone system in the progression of chronic kidney disease. Kidney International. 2005;99:S57–65. DOI: 10.1111/j.1523-1755.2005.09911.xBalakumar P, Jagadeesh G. A century old renin–angiotensin system still grows with endless possibilities: AT1 receptor signaling cascades in cardiovascular physiopathology. Cellular Signalling. 2014;26(10):2147–60. DOI: 10.1016/j.cellsig.2014.06.011Balakumar P, Jagadeesh G. A century old renin–angiotensin system still grows with endless possibilities: AT1 receptor signaling cascades in cardiovascular physiopathology. Cellular Signalling. 2014;26(10):2147–60. DOI: 10.1016/j.cellsig.2014.06.011Peltonen T, Ohukainen P, Ruskoaho H, Rysä J. Targeting vasoactive peptides for managing calcific aortic valve disease. Annals of Medicine. 2017;49(1):63–74. DOI: 10.1080/07853890.2016.1231933Peltonen T, Ohukainen P, Ruskoaho H, Rysä J. Targeting vasoactive peptides for managing calcific aortic valve disease. Annals of Medicine. 2017;49(1):63–74. DOI: 10.1080/07853890.2016.1231933Karnik SS, Unal H, Kemp JR, Tirupula KC, Eguchi S, Vanderheyden PML et al. International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli. Pharmacological Reviews. 2015;67(4):754–819. DOI: 10.1124/pr.114.010454Karnik SS, Unal H, Kemp JR, Tirupula KC, Eguchi S, Vanderheyden PML et al. International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli. Pharmacological Reviews. 2015;67(4):754–819. DOI: 10.1124/pr.114.010454Helske S, Lindstedt KA, Laine M, Mäyränpää M, Werkkala K, Lommi J et al. Induction of local angiotensin II-producing systems in stenotic aortic valves. Journal of the American College of Cardiology. 2004;44(9):1859–66. DOI: 10.1016/j.jacc.2004.07.054Helske S, Lindstedt KA, Laine M, Mäyränpää M, Werkkala K, Lommi J et al. Induction of local angiotensin II-producing systems in stenotic aortic valves. Journal of the American College of Cardiology. 2004;44(9):1859–66. DOI: 10.1016/j.jacc.2004.07.054Peltonen T, Näpänkangas J, Vuolteenaho O, Ohtonen P, Soini Y, Juvonen T et al. Apelin and its receptor APJ in human aortic valve stenosis. The Journal of Heart Valve Disease. 2009;18(6):644–52. PMID: 20099713Peltonen T, Näpänkangas J, Vuolteenaho O, Ohtonen P, Soini Y, Juvonen T et al. Apelin and its receptor APJ in human aortic valve stenosis. The Journal of Heart Valve Disease. 2009;18(6):644–52. PMID: 20099713O’Brien KD, Shavelle DM, Caulfield MT, McDonald TO, OlinLewis K, Otto CM et al. Association of angiotensin-converting enzyme with low-density lipoprotein in aortic valvular lesions and in human plasma. Circulation. 2002;106(17):2224–30. DOI: 10.1161/01.cir.0000035655.45453.d2O’Brien KD, Shavelle DM, Caulfield MT, McDonald TO, OlinLewis K, Otto CM et al. Association of angiotensin-converting enzyme with low-density lipoprotein in aortic valvular lesions and in human plasma. Circulation. 2002;106(17):2224–30. DOI: 10.1161/01.cir.0000035655.45453.d2Li XC, Zhuo JL. Nuclear factor-κB as a hormonal intracellular signaling molecule: focus on angiotensin II-induced cardiovascular and renal injury: Current Opinion in Nephrology and Hypertension. 2008;17(1):37–43. DOI: 10.1097/MNH.0b013e3282f2903cLi XC, Zhuo JL. Nuclear factor-κB as a hormonal intracellular signaling molecule: focus on angiotensin II-induced cardiovascular and renal injury: Current Opinion in Nephrology and Hypertension. 2008;17(1):37–43. DOI: 10.1097/MNH.0b013e3282f2903cZablocki D, Sadoshima J. Angiotensin II and Oxidative Stress in the Failing Heart. Antioxidants & Redox Signaling. 2013;19(10):1095–109. DOI: 10.1089/ars.2012.4588Zablocki D, Sadoshima J. Angiotensin II and Oxidative Stress in the Failing Heart. Antioxidants & Redox Signaling. 2013;19(10):1095–109. DOI: 10.1089/ars.2012.4588Liberman M, Bassi E, Martinatti MK, Lario FC, Wosniak J, Pomerantzeff PMA et al. Oxidant Generation Predominates Around Calcifying Foci and Enhances Progression of Aortic Valve Calcification. Arteriosclerosis, Thrombosis, and Vascular Biology. 2008;28(3):463–70. DOI: 10.1161/ATVBAHA.107.156745Liberman M, Bassi E, Martinatti MK, Lario FC, Wosniak J, Pomerantzeff PMA et al. Oxidant Generation Predominates Around Calcifying Foci and Enhances Progression of Aortic Valve Calcification. Arteriosclerosis, Thrombosis, and Vascular Biology. 2008;28(3):463–70. DOI: 10.1161/ATVBAHA.107.156745Miller JD, Chu Y, Brooks RM, Richenbacher WE, Peña-Silva R, Heistad DD. Dysregulation of Antioxidant Mechanisms Contributes to Increased Oxidative Stress in Calcific Aortic Valvular Stenosis in Humans. Journal of the American College of Cardiology. 2008;52(10):843–50. DOI: 10.1016/j.jacc.2008.05.043Miller JD, Chu Y, Brooks RM, Richenbacher WE, Peña-Silva R, Heistad DD. Dysregulation of Antioxidant Mechanisms Contributes to Increased Oxidative Stress in Calcific Aortic Valvular Stenosis in Humans. Journal of the American College of Cardiology. 2008;52(10):843–50. DOI: 10.1016/j.jacc.2008.05.043Rajamannan N. Role of Oxidative Stress in Calcific Aortic Valve Disease: From Bench to Bedside - The Role of a Stem Cell Niche. In: Oxidative Stress and Chronic Degenerative Diseases - A Role for Antioxidants Morales-Gonzalez JA, editor -Croatia: InTech;2013.Rajamannan N. Role of Oxidative Stress in Calcific Aortic Valve Disease: From Bench to Bedside - The Role of a Stem Cell Niche. In: Oxidative Stress and Chronic Degenerative Diseases - A Role for Antioxidants Morales-Gonzalez JA, editor -Croatia: InTech;2013.Morgan MJ, Liu Z. Reactive oxygen species in TNFα-induced signaling and cell death. Molecules and Cells. 2010;30(1):1–12. DOI: 10.1007/s10059-010-0105-0Morgan MJ, Liu Z. Reactive oxygen species in TNFα-induced signaling and cell death. Molecules and Cells. 2010;30(1):1–12. DOI: 10.1007/s10059-010-0105-0Belhadj Slimen I, Najar T, Ghram A, Dabbebi H, Ben Mrad M, Abdrabbah M. Reactive oxygen species, heat stress and oxidative-induced mitochondrial damage. A review. International Journal of Hyperthermia. 2014;30(7):513–23. DOI: 10.3109/02656736.2014.971446Belhadj Slimen I, Najar T, Ghram A, Dabbebi H, Ben Mrad M, Abdrabbah M. Reactive oxygen species, heat stress and oxidative-induced mitochondrial damage. A review. International Journal of Hyperthermia. 2014;30(7):513–23. DOI: 10.3109/02656736.2014.971446Xie C, Shen Y, Hu W, Chen Z, Li Y. Angiotensin II promotes an osteoblast-like phenotype in porcine aortic valve myofibroblasts. Aging Clinical and Experimental Research. 2016;28(2):181–7. DOI: 10.1007/s40520-015-0408-2Xie C, Shen Y, Hu W, Chen Z, Li Y. Angiotensin II promotes an osteoblast-like phenotype in porcine aortic valve myofibroblasts. Aging Clinical and Experimental Research. 2016;28(2):181–7. DOI: 10.1007/s40520-015-0408-2Fujisaka T, Hoshiga M, Hotchi J, Takeda Y, Jin D, Takai S et al. Angiotensin II promotes aortic valve thickening independent of elevated blood pressure in apolipoprotein-E deficient mice. Atherosclerosis. 2013;226(1):82–7. DOI: 10.1016/j.atherosclerosis.2012.10.055Fujisaka T, Hoshiga M, Hotchi J, Takeda Y, Jin D, Takai S et al. Angiotensin II promotes aortic valve thickening independent of elevated blood pressure in apolipoprotein-E deficient mice. Atherosclerosis. 2013;226(1):82–7. DOI: 10.1016/j.atherosclerosis.2012.10.055Arishiro K, Hoshiga M, Negoro N, Jin D, Takai S, Miyazaki M et al. Angiotensin Receptor-1 Blocker Inhibits Atherosclerotic Changes and Endothelial Disruption of the Aortic Valve in Hypercholesterolemic Rabbits. Journal of the American College of Cardiology. 2007;49(13):1482–9. DOI: 10.1016/j.jacc.2006.11.043Arishiro K, Hoshiga M, Negoro N, Jin D, Takai S, Miyazaki M et al. Angiotensin Receptor-1 Blocker Inhibits Atherosclerotic Changes and Endothelial Disruption of the Aortic Valve in Hypercholesterolemic Rabbits. Journal of the American College of Cardiology. 2007;49(13):1482–9. DOI: 10.1016/j.jacc.2006.11.043Masuda C, Dohi K, Sakurai Y, Bessho Y, Fukuda H, Fujii S et al. Impact of Chronic Kidney Disease on the Presence and Severity of Aortic Stenosis in Patients at High Risk for Coronary Artery Disease. Cardiovascular Ultrasound. 2011;9(1):31. DOI: 10.1186/1476-7120-9-31Masuda C, Dohi K, Sakurai Y, Bessho Y, Fukuda H, Fujii S et al. Impact of Chronic Kidney Disease on the Presence and Severity of Aortic Stenosis in Patients at High Risk for Coronary Artery Disease. Cardiovascular Ultrasound. 2011;9(1):31. DOI: 10.1186/1476-7120-9-31Rieck ÅE, Cramariuc D, Boman K, Gohlke-Bärwolf C, Staal EM, Lønnebakken MT et al. Hypertension in Aortic Stenosis: Implications for Left Ventricular Structure and Cardiovascular Events. Hypertension. 2012;60(1):90–7. DOI: 10.1161/HYPERTENSIONAHA.112.194878Rieck ÅE, Cramariuc D, Boman K, Gohlke-Bärwolf C, Staal EM, Lønnebakken MT et al. Hypertension in Aortic Stenosis: Implications for Left Ventricular Structure and Cardiovascular Events. Hypertension. 2012;60(1):90–7. DOI: 10.1161/HYPERTENSIONAHA.112.194878Perkovic V, Hunt D, Griffin SV, du Plessis M, Becker GJ. Accelerated Progression of Calcific Aortic Stenosis in Dialysis Patients. Nephron Clinical Practice. 2004;94(2):c40–5. DOI: 10.1159/000071280Perkovic V, Hunt D, Griffin SV, du Plessis M, Becker GJ. Accelerated Progression of Calcific Aortic Stenosis in Dialysis Patients. Nephron Clinical Practice. 2004;94(2):c40–5. DOI: 10.1159/000071280Tastet L, Capoulade R, Clavel M-A, Larose É, Shen M, Dahou A et al. Systolic hypertension and progression of aortic valve calcification in patients with aortic stenosis: results from the PROGRESSA study. European Heart Journal – Cardiovascular Imaging. 2017;18(1):70–8. DOI: 10.1093/ehjci/jew013Tastet L, Capoulade R, Clavel M-A, Larose É, Shen M, Dahou A et al. Systolic hypertension and progression of aortic valve calcification in patients with aortic stenosis: results from the PROGRESSA study. European Heart Journal – Cardiovascular Imaging. 2017;18(1):70–8. DOI: 10.1093/ehjci/jew013Liakos CI, Grassos CA, Papadopoulos DP, Dimitriadis KS, Tsioufis CP, Tousoulis D. Arterial hypertension and aortic valve stenosis: Shedding light on a common “liaison”. Hellenic Journal of Cardiology. 2017;58(4):261–6. DOI: 10.1016/j.hjc.2017.03.005Liakos CI, Grassos CA, Papadopoulos DP, Dimitriadis KS, Tsioufis CP, Tousoulis D. Arterial hypertension and aortic valve stenosis: Shedding light on a common “liaison”. Hellenic Journal of Cardiology. 2017;58(4):261–6. DOI: 10.1016/j.hjc.2017.03.005Dweck MR, Boon NA, Newby DE. Calcific Aortic Stenosis: a disease of the valve and the myocardium. Journal of the American College of Cardiology. 2012;60(19):1854–63. DOI: 10.1016/j.jacc.2012.02.093Dweck MR, Boon NA, Newby DE. Calcific Aortic Stenosis: a disease of the valve and the myocardium. Journal of the American College of Cardiology. 2012;60(19):1854–63. DOI: 10.1016/j.jacc.2012.02.093Rattazzi M, Bertacco E, Del Vecchio A, Puato M, Faggin E, Pauletto P. Aortic valve calcification in chronic kidney disease. Nephrology Dialysis Transplantation. 2013;28(12):2968–76. DOI: 10.1093/ndt/gft310Rattazzi M, Bertacco E, Del Vecchio A, Puato M, Faggin E, Pauletto P. Aortic valve calcification in chronic kidney disease. Nephrology Dialysis Transplantation. 2013;28(12):2968–76. DOI: 10.1093/ndt/gft310Ahmad S, Varagic J, VonCannon JL, Groban L, Collawn JF, Dell’Italia LJ et al. Primacy of cardiac chymase over angiotensin converting enzyme as an angiotensin-(1-12) metabolizing enzyme. Biochemical and Biophysical Research Communications. 2016;478(2):559–64. DOI: 10.1016/j.bbrc.2016.07.100Ahmad S, Varagic J, VonCannon JL, Groban L, Collawn JF, Dell’Italia LJ et al. Primacy of cardiac chymase over angiotensin converting enzyme as an angiotensin-(1-12) metabolizing enzyme. Biochemical and Biophysical Research Communications. 2016;478(2):559–64. DOI: 10.1016/j.bbrc.2016.07.100Nagata S, Hatakeyama K, Asami M, Tokashiki M, Hibino H, Nishiuchi Y et al. Big angiotensin-25: A novel glycosylated angiotensin-related peptide isolated from human urine. Biochemical and Biophysical Research Communications. 2013;441(4):757–62. DOI: 10.1016/j.bbrc.2013.10.124Nagata S, Hatakeyama K, Asami M, Tokashiki M, Hibino H, Nishiuchi Y et al. Big angiotensin-25: A novel glycosylated angiotensin-related peptide isolated from human urine. Biochemical and Biophysical Research Communications. 2013;441(4):757–62. DOI: 10.1016/j.bbrc.2013.10.124Nagata S, Kato J, Sasaki K, Minamino N, Eto T, Kitamura K. Isolation and identification of proangiotensin-12, a possible component of the renin–angiotensin system. Biochemical and Biophysical Research Communications. 2006;350(4):1026–31. DOI: 10.1016/j.bbrc.2006.09.146Nagata S, Kato J, Sasaki K, Minamino N, Eto T, Kitamura K. Isolation and identification of proangiotensin-12, a possible component of the renin–angiotensin system. Biochemical and Biophysical Research Communications. 2006;350(4):1026–31. DOI: 10.1016/j.bbrc.2006.09.146Ahmad S, Simmons T, Varagic J, Moniwa N, Chappell MC, Ferrario CM. Chymase-Dependent Generation of Angiotensin II from Angiotensin-(1-12) in Human Atrial Tissue. PLoS ONE. 2011;6(12):e28501. DOI: 10.1371/journal.pone.0028501Ahmad S, Simmons T, Varagic J, Moniwa N, Chappell MC, Ferrario CM. Chymase-Dependent Generation of Angiotensin II from Angiotensin-(1-12) in Human Atrial Tissue. PLoS ONE. 2011;6(12):e28501. DOI: 10.1371/journal.pone.0028501Ahmad S, Wei C-C, Tallaj J, Dell’Italia LJ, Moniwa N, Varagic J et al. Chymase mediates angiotensin-(1-12) metabolism in normal human hearts. Journal of the American Society of Hypertension. 2013;7(2):128–36. DOI: 10.1016/j.jash.2012.12.003Ahmad S, Wei C-C, Tallaj J, Dell’Italia LJ, Moniwa N, Varagic J et al. Chymase mediates angiotensin-(1-12) metabolism in normal human hearts. Journal of the American Society of Hypertension. 2013;7(2):128–36. DOI: 10.1016/j.jash.2012.12.003Helske S, Syväranta S, Kupari M, Lappalainen J, Laine M, Lommi J et al. Possible role for mast cell-derived cathepsin G in the adverse remodelling of stenotic aortic valves. European Heart Journal. 2006;27(12):1495–504. DOI: 10.1093/eurheartj/ehi706Helske S, Syväranta S, Kupari M, Lappalainen J, Laine M, Lommi J et al. Possible role for mast cell-derived cathepsin G in the adverse remodelling of stenotic aortic valves. European Heart Journal. 2006;27(12):1495–504. DOI: 10.1093/eurheartj/ehi706Coté N, Mahmut A, Bosse Y, Couture C, Pagé S, Trahan S et al. Inflammation Is Associated with the Remodeling of Calcific Aortic Valve Disease. Inflammation. 2013;36(3):573–81. DOI: 10.1007/s10753-012-9579-6Coté N, Mahmut A, Bosse Y, Couture C, Pagé S, Trahan S et al. Inflammation Is Associated with the Remodeling of Calcific Aortic Valve Disease. Inflammation. 2013;36(3):573–81. DOI: 10.1007/s10753-012-9579-6Šteiner I, Krbal L, Rozkoš T, Harrer J, Laco J. Calcific aortic valve stenosis: Immunohistochemical analysis of inflammatory infiltrate. Pathology - Research and Practice. 2012;208(4):231–4. DOI: 10.1016/j.prp.2012.02.009Šteiner I, Krbal L, Rozkoš T, Harrer J, Laco J. Calcific aortic valve stenosis: Immunohistochemical analysis of inflammatory infiltrate. Pathology - Research and Practice. 2012;208(4):231–4. DOI: 10.1016/j.prp.2012.02.009Šteiner I, Stejskal V, Žáček P. Mast cells in calcific aortic stenosis. Pathology – Research and Practice. 2018;214(1):163–8. DOI: 10.1016/j.prp.2017.07.016Šteiner I, Stejskal V, Žáček P. Mast cells in calcific aortic stenosis. Pathology – Research and Practice. 2018;214(1):163–8. DOI: 10.1016/j.prp.2017.07.016O’Brien KD, Reichenbach DD, Marcovina SM, Kuusisto J, Alpers CE, Otto CM. Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of ‘degenerative’ valvular aortic stenosis. Arteriosclerosis, Thrombosis, and Vascular Biology. 1996;16(4):523–32. DOI: 10.1161/01.atv.16.4.523O’Brien KD, Reichenbach DD, Marcovina SM, Kuusisto J, Alpers CE, Otto CM. Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of ‘degenerative’ valvular aortic stenosis. Arteriosclerosis, Thrombosis, and Vascular Biology. 1996;16(4):523–32. DOI: 10.1161/01.atv.16.4.523Olsson M, Thyberg J, Nilsson J. Presence of oxidized low density lipoprotein in nonrheumatic stenotic aortic valves. Arteriosclerosis, Thrombosis, and Vascular Biology. 1999;19(5):1218–22. DOI: 10.1161/01.atv.19.5.1218Olsson M, Thyberg J, Nilsson J. Presence of oxidized low density lipoprotein in nonrheumatic stenotic aortic valves. Arteriosclerosis, Thrombosis, and Vascular Biology. 1999;19(5):1218–22. DOI: 10.1161/01.atv.19.5.1218Parisi V, Leosco D, Ferro G, Bevilacqua A, Pagano G, de Lucia C et al. The lipid theory in the pathogenesis of calcific aortic stenosis. Nutrition, Metabolism and Cardiovascular Diseases. 2015;25(6):519–25. DOI: 10.1016/j.numecd.2015.02.001Parisi V, Leosco D, Ferro G, Bevilacqua A, Pagano G, de Lucia C et al. The lipid theory in the pathogenesis of calcific aortic stenosis. Nutrition, Metabolism and Cardiovascular Diseases. 2015;25(6):519–25. DOI: 10.1016/j.numecd.2015.02.001Mohty D, Pibarot P, Després J-P, Côté C, Arsenault B, Cartier A et al. Association Between Plasma LDL Particle Size, Valvular Accumulation of Oxidized LDL, and Inflammation in Patients with Aortic Stenosis. Arteriosclerosis, Thrombosis, and Vascular Biology. 2008;28(1):187–93. DOI: 10.1161/ATVBAHA.107.154989Mohty D, Pibarot P, Després J-P, Côté C, Arsenault B, Cartier A et al. Association Between Plasma LDL Particle Size, Valvular Accumulation of Oxidized LDL, and Inflammation in Patients with Aortic Stenosis. Arteriosclerosis, Thrombosis, and Vascular Biology. 2008;28(1):187–93. DOI: 10.1161/ATVBAHA.107.154989Tiede K, Stöter K, Petrik C, Chen WB, Ungefroren H, Kruse ML et al. Angiotensin II AT(1)-receptor induces biglycan in neonatal cardiac fibroblasts via autocrine release of TGFbeta in vitro. Cardiovascular Research. 2003;60(3):538–46. DOI: 10.1016/j.cardiores.2003.08.009Tiede K, Stöter K, Petrik C, Chen WB, Ungefroren H, Kruse ML et al. Angiotensin II AT(1)-receptor induces biglycan in neonatal cardiac fibroblasts via autocrine release of TGFbeta in vitro. Cardiovascular Research. 2003;60(3):538–46. DOI: 10.1016/j.cardiores.2003.08.009Neufeld EB, Zadrozny LM, Phillips D, Aponte A, Yu Z-X, Balaban RS. Decorin and biglycan retain LDL in disease-prone valvular and aortic subendothelial intimal matrix. Atherosclerosis. 2014;233(1):113–21. DOI: 10.1016/j.atherosclerosis.2013.12.038Neufeld EB, Zadrozny LM, Phillips D, Aponte A, Yu Z-X, Balaban RS. Decorin and biglycan retain LDL in disease-prone valvular and aortic subendothelial intimal matrix. Atherosclerosis. 2014;233(1):113–21. DOI: 10.1016/j.atherosclerosis.2013.12.038Osman N, Grande-Allen KJ, Ballinger ML, Getachew R, Marasco S, O’Brien KD et al. Smad2-dependent glycosaminoglycan elongation in aortic valve interstitial cells enhances binding of LDL to proteoglycans. Cardiovascular Pathology. 2013;22(2):146–55. DOI: 10.1016/j.carpath.2012.07.002Osman N, Grande-Allen KJ, Ballinger ML, Getachew R, Marasco S, O’Brien KD et al. Smad2-dependent glycosaminoglycan elongation in aortic valve interstitial cells enhances binding of LDL to proteoglycans. Cardiovascular Pathology. 2013;22(2):146–55. DOI: 10.1016/j.carpath.2012.07.002Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circulation Research. 2000;87(5):E1-9. DOI: 10.1161/01.res.87.5.e1Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circulation Research. 2000;87(5):E1-9. DOI: 10.1161/01.res.87.5.e1Ferreira AJ, Santos RAS, Bradford CN, Mecca AP, Sumners C, Katovich MJ et al. Therapeutic Implications of the Vasoprotective Axis of the Renin-Angiotensin System in Cardiovascular Diseases. Hypertension. 2010;55(2):207–13. DOI: 10.1161/HYPERTENSIONAHA.109.140145Ferreira AJ, Santos RAS, Bradford CN, Mecca AP, Sumners C, Katovich MJ et al. Therapeutic Implications of the Vasoprotective Axis of the Renin-Angiotensin System in Cardiovascular Diseases. Hypertension. 2010;55(2):207–13. DOI: 10.1161/HYPERTENSIONAHA.109.140145Iwai M, Horiuchi M. Devil and angel in the renin–angiotensin system: ACE–angiotensin II–AT1 receptor axis vs. ACE2–angiotensin-(1–7)–Mas receptor axis. Hypertension Research. 2009;32(7):533–6. DOI: 10.1038/hr.2009.74Iwai M, Horiuchi M. Devil and angel in the renin–angiotensin system: ACE–angiotensin II–AT1 receptor axis vs. ACE2–angiotensin-(1–7)–Mas receptor axis. Hypertension Research. 2009;32(7):533–6. DOI: 10.1038/hr.2009.74Alenina N, Xu P, Rentzsch B, Patkin EL, Bader M. Genetically altered animal models for Mas and angiotensin-(1-7): Transgenic animal models for Mas and angiotensin-(1-7). Experimental Physiology. 2008;93(5):528–37. DOI: 10.1113/expphysiol.2007.040345Alenina N, Xu P, Rentzsch B, Patkin EL, Bader M. Genetically altered animal models for Mas and angiotensin-(1-7): Transgenic animal models for Mas and angiotensin-(1-7). Experimental Physiology. 2008;93(5):528–37. DOI: 10.1113/expphysiol.2007.040345Kassiri Z, Zhong J, Guo D, Basu R, Wang X, Liu PP et al. Loss of Angiotensin-Converting Enzyme 2 Accelerates Maladaptive Left Ventricular Remodeling in Response to Myocardial Infarction. Circulation: Heart Failure. 2009;2(5):446–55. DOI: 10.1161/CIRCHEARTFAILURE.108.840124Kassiri Z, Zhong J, Guo D, Basu R, Wang X, Liu PP et al. Loss of Angiotensin-Converting Enzyme 2 Accelerates Maladaptive Left Ventricular Remodeling in Response to Myocardial Infarction. Circulation: Heart Failure. 2009;2(5):446–55. DOI: 10.1161/CIRCHEARTFAILURE.108.840124Zhong J, Basu R, Guo D, Chow FL, Byrns S, Schuster M et al. Angiotensin-Converting Enzyme 2 Suppresses Pathological Hypertrophy, Myocardial Fibrosis, and Cardiac Dysfunction. Circulation. 2010;122(7):717–28. DOI: 10.1161/CIRCULATIONAHA.110.955369Zhong J, Basu R, Guo D, Chow FL, Byrns S, Schuster M et al. Angiotensin-Converting Enzyme 2 Suppresses Pathological Hypertrophy, Myocardial Fibrosis, and Cardiac Dysfunction. Circulation. 2010;122(7):717–28. DOI: 10.1161/CIRCULATIONAHA.110.955369Trask AJ, Groban L, Westwood BM, Varagic J, Ganten D, Gallagher PE et al. Inhibition of Angiotensin-Converting Enzyme 2 Exacerbates Cardiac Hypertrophy and Fibrosis in Ren-2 Hypertensive Rats. American Journal of Hypertension. 2010;23(6):687–93. DOI: 10.1038/ajh.2010.51Trask AJ, Groban L, Westwood BM, Varagic J, Ganten D, Gallagher PE et al. Inhibition of Angiotensin-Converting Enzyme 2 Exacerbates Cardiac Hypertrophy and Fibrosis in Ren-2 Hypertensive Rats. American Journal of Hypertension. 2010;23(6):687–93. DOI: 10.1038/ajh.2010.51Peltonen T, Näpänkangas J, Ohtonen P, Aro J, Peltonen J, Soini Y et al. (Pro)renin receptors and angiotensin converting enzyme 2/angiotensin-(1-7)/Mas receptor axis in human aortic valve stenosis. Atherosclerosis. 2011;216(1):35–43. DOI: 10.1016/j.atherosclerosis.2011.01.018Peltonen T, Näpänkangas J, Ohtonen P, Aro J, Peltonen J, Soini Y et al. (Pro)renin receptors and angiotensin converting enzyme 2/angiotensin-(1-7)/Mas receptor axis in human aortic valve stenosis. Atherosclerosis. 2011;216(1):35–43. DOI: 10.1016/j.atherosclerosis.2011.01.018Collister JP, Nahey DB. Simultaneous administration of Ang(1-7) or A-779 does not affect the chronic hypertensive effects of angiotensin II in normal rats. Journal of the Renin-Angiotensin-Aldosterone System. 2010;11(2):99–102. DOI: 10.1177/1470320309359928Collister JP, Nahey DB. Simultaneous administration of Ang(1-7) or A-779 does not affect the chronic hypertensive effects of angiotensin II in normal rats. Journal of the Renin-Angiotensin-Aldosterone System. 2010;11(2):99–102. DOI: 10.1177/1470320309359928Velkoska E, Dean RG, Griggs K, Burchill L, Burrell LM. Angiotensin-(1–7) infusion is associated with increased blood pressure and adverse cardiac remodelling in rats with subtotal nephrectomy. Clinical Science. 2011;120(8):335–45. DOI: 10.1042/CS20100280Velkoska E, Dean RG, Griggs K, Burchill L, Burrell LM. Angiotensin-(1–7) infusion is associated with increased blood pressure and adverse cardiac remodelling in rats with subtotal nephrectomy. Clinical Science. 2011;120(8):335–45. DOI: 10.1042/CS20100280Shao Y, He M, Zhou L, Yao T, Huang Y, Lu L. Chronic angiotensin (17) injection accelerates STZ-induced diabetic renal injury 1. Acta Pharmacologica Sinica. 2008;29(7):829–37. DOI: 10.1111/j.1745-7254.2008.00812.xShao Y, He M, Zhou L, Yao T, Huang Y, Lu L. Chronic angiotensin (17) injection accelerates STZ-induced diabetic renal injury 1. Acta Pharmacologica Sinica. 2008;29(7):829–37. DOI: 10.1111/j.1745-7254.2008.00812.xMendoza-Torres E, Oyarzún A, Mondaca-Ruff D, Azocar A, Castro PF, Jalil JE et al. ACE2 and vasoactive peptides: novel players in cardiovascular/renal remodeling and hypertension. Therapeutic Advances in Cardiovascular Disease. 2015;9(4):217–37. DOI: 10.1177/1753944715597623Mendoza-Torres E, Oyarzún A, Mondaca-Ruff D, Azocar A, Castro PF, Jalil JE et al. ACE2 and vasoactive peptides: novel players in cardiovascular/renal remodeling and hypertension. Therapeutic Advances in Cardiovascular Disease. 2015;9(4):217–37. DOI: 10.1177/1753944715597623Westermeier F, Bustamante M, Pavez M, García L, Chiong M, Ocaranza MP et al. Novel players in cardioprotection: Insulin like growth factor-1, angiotensin-(1–7) and angiotensin-(1–9). Pharmacological Research. 2015;101:41–55. DOI: 10.1016/j.phrs.2015.06.018Westermeier F, Bustamante M, Pavez M, García L, Chiong M, Ocaranza MP et al. Novel players in cardioprotection: Insulin like growth factor-1, angiotensin-(1–7) and angiotensin-(1–9). Pharmacological Research. 2015;101:41–55. DOI: 10.1016/j.phrs.2015.06.018Ocaranza MP, Lavandero S, Jalil JE, Moya J, Pinto M, Novoa U et al. Angiotensin-(1–9) regulates cardiac hypertrophy in vivo and in vitro. Journal of Hypertension. 2010;28(5):1054–64. DOI: 10.1097/HJH.0b013e328335d291Ocaranza MP, Lavandero S, Jalil JE, Moya J, Pinto M, Novoa U et al. Angiotensin-(1–9) regulates cardiac hypertrophy in vivo and in vitro. Journal of Hypertension. 2010;28(5):1054–64. DOI: 10.1097/HJH.0b013e328335d291Ocaranza MP, Moya J, Barrientos V, Alzamora R, Hevia D, Morales C et al. Angiotensin-(1–9) reverses experimental hypertension and cardiovascular damage by inhibition of the angiotensin converting enzyme/Ang II axis: Journal of Hypertension. 2014;32(4):771–83. DOI: 10.1097/HJH.0000000000000094Ocaranza MP, Moya J, Barrientos V, Alzamora R, Hevia D, Morales C et al. Angiotensin-(1–9) reverses experimental hypertension and cardiovascular damage by inhibition of the angiotensin converting enzyme/Ang II axis: Journal of Hypertension. 2014;32(4):771–83. DOI: 10.1097/HJH.0000000000000094Zheng H, Pu S-Y, Fan X-F, Li X-S, Zhang Y, Yuan J et al. Treatment with angiotensin-(1-9) alleviates the cardiomyopathy in streptozotocin-induced diabetic rats. Biochemical Pharmacology. 2015;95(1):38–45. DOI: 10.1016/j.bcp.2015.03.009Zheng H, Pu S-Y, Fan X-F, Li X-S, Zhang Y, Yuan J et al. Treatment with angiotensin-(1-9) alleviates the cardiomyopathy in streptozotocin-induced diabetic rats. Biochemical Pharmacology. 2015;95(1):38–45. DOI: 10.1016/j.bcp.2015.03.009Cha SAh, Park BM, Gao S, Kim SH. Stimulation of ANP by angiotensin-(1-9) via the angiotensin type 2 receptor. Life Sciences. 2013;93(24):934–40. DOI: 10.1016/j.lfs.2013.10.020Cha SAh, Park BM, Gao S, Kim SH. Stimulation of ANP by angiotensin-(1-9) via the angiotensin type 2 receptor. Life Sciences. 2013;93(24):934–40. DOI: 10.1016/j.lfs.2013.10.020Flores-Munoz M, Work LM, Douglas K, Denby L, Dominiczak AF, Graham D et al. Angiotensin-(1-9) Attenuates Cardiac Fibrosis in the Stroke-Prone Spontaneously Hypertensive Rat via the Angiotensin Type 2 Receptor. Hypertension. 2012;59(2):300–7. DOI: 10.1161/HYPERTENSIONAHA.111.177485Flores-Munoz M, Work LM, Douglas K, Denby L, Dominiczak AF, Graham D et al. Angiotensin-(1-9) Attenuates Cardiac Fibrosis in the Stroke-Prone Spontaneously Hypertensive Rat via the Angiotensin Type 2 Receptor. Hypertension. 2012;59(2):300–7. DOI: 10.1161/HYPERTENSIONAHA.111.177485Yu L, Yuan K, Phuong HTA, Park BM, Kim SH. Angiotensin-(1-5), an active mediator of renin-angiotensin system, stimulates ANP secretion via Mas receptor. Peptides. 2016;86:33–41. DOI: 10.1016/j.peptides.2016.09.009Yu L, Yuan K, Phuong HTA, Park BM, Kim SH. Angiotensin-(1-5), an active mediator of renin-angiotensin system, stimulates ANP secretion via Mas receptor. Peptides. 2016;86:33–41. DOI: 10.1016/j.peptides.2016.09.009Hrenak J, Paulis L, Simko F. Angiotensin A/Alamandine/MrgD Axis: Another Clue to Understanding Cardiovascular Pathophysiology. International Journal of Molecular Sciences. 2016;17(7):1098. DOI: 10.3390/ijms17071098Hrenak J, Paulis L, Simko F. Angiotensin A/Alamandine/MrgD Axis: Another Clue to Understanding Cardiovascular Pathophysiology. International Journal of Molecular Sciences. 2016;17(7):1098. DOI: 10.3390/ijms17071098Lautner RQ, Villela DC, Fraga-Silva RA, Silva N, Verano-Braga T, CostaFraga F et al. Discovery and Characterization of Alamandine: A Novel Component of the Renin–Angiotensin System. Circulation Research. 2013;112(8):1104–11. DOI: 10.1161/CIRCRESAHA.113.301077Lautner RQ, Villela DC, Fraga-Silva RA, Silva N, Verano-Braga T, CostaFraga F et al. Discovery and Characterization of Alamandine: A Novel Component of the Renin–Angiotensin System. Circulation Research. 2013;112(8):1104–11. DOI: 10.1161/CIRCRESAHA.113.301077Villela DC, Passos-Silva DG, Santos RAS. Alamandine: a new member of the angiotensin family. Current Opinion in Nephrology and Hypertension. 2014;23(2):130–4. DOI: 10.1097/01.mnh.0000441052.44406.92Villela DC, Passos-Silva DG, Santos RAS. Alamandine: a new member of the angiotensin family. Current Opinion in Nephrology and Hypertension. 2014;23(2):130–4. DOI: 10.1097/01.mnh.0000441052.44406.92Habiyakare B, Alsaadon H, Mathai ML, Hayes A, Zulli A. Reduction of angiotensin A and alamandine vasoactivity in the rabbit model of atherogenesis: differential effects of alamandine and Ang(1-7). International Journal of Experimental Pathology. 2014;95(4):290–5. DOI: 10.1111/iep.12087Habiyakare B, Alsaadon H, Mathai ML, Hayes A, Zulli A. Reduction of angiotensin A and alamandine vasoactivity in the rabbit model of atherogenesis: differential effects of alamandine and Ang(1-7). International Journal of Experimental Pathology. 2014;95(4):290–5. DOI: 10.1111/iep.12087Jankowski V, Tölle M, Santos RAS, Günthner T, Krause E, Beyermann M et al. Angioprotectin: an angiotensin II-like peptide causing vasodilatory effects. The FASEB Journal. 2011;25(9):2987–95. DOI: 10.1096/fj.11-185470Jankowski V, Tölle M, Santos RAS, Günthner T, Krause E, Beyermann M et al. Angioprotectin: an angiotensin II-like peptide causing vasodilatory effects. The FASEB Journal. 2011;25(9):2987–95. DOI: 10.1096/fj.11-185470Jankowski V, Vanholder R, van der Giet M, Tölle M, Karadogan S, Gobom J et al. Mass-Spectrometric Identification of a Novel Angiotensin Peptide in Human Plasma. Arteriosclerosis, Thrombosis, and Vascular Biology. 2007;27(2):297–302. DOI: 10.1161/01.ATV.0000253889.09765.5fJankowski V, Vanholder R, van der Giet M, Tölle M, Karadogan S, Gobom J et al. Mass-Spectrometric Identification of a Novel Angiotensin Peptide in Human Plasma. Arteriosclerosis, Thrombosis, and Vascular Biology. 2007;27(2):297–302. DOI: 10.1161/01.ATV.0000253889.09765.5fYang R, Smolders I, Vanderheyden P, Demaegdt H, Van Eeckhaut A, Vauquelin G et al. Pressor and Renal Hemodynamic Effects of the Novel Angiotensin A Peptide Are Angiotensin II Type 1A Receptor Dependent. Hypertension. 2011;57(5):956–64. DOI: 10.1161/HYPERTENSIONAHA.110.161836Yang R, Smolders I, Vanderheyden P, Demaegdt H, Van Eeckhaut A, Vauquelin G et al. Pressor and Renal Hemodynamic Effects of the Novel Angiotensin A Peptide Are Angiotensin II Type 1A Receptor Dependent. Hypertension. 2011;57(5):956–64. DOI: 10.1161/HYPERTENSIONAHA.110.161836Coutinho DC, Foureaux G, Rodrigues KD, Salles RL, Moraes PL, Murça TM et al. Cardiovascular effects of angiotensin A: A novel peptide of the renin–angiotensin system. Journal of the ReninAngiotensin-Aldosterone System. 2014;15(4):480–6. DOI: 10.1177/1470320312474856Coutinho DC, Foureaux G, Rodrigues KD, Salles RL, Moraes PL, Murça TM et al. Cardiovascular effects of angiotensin A: A novel peptide of the renin–angiotensin system. Journal of the ReninAngiotensin-Aldosterone System. 2014;15(4):480–6. DOI: 10.1177/1470320312474856Ngo DT, Stafford I, Sverdlov AL, Qi W, Wuttke RD, Zhang Y et al. Ramipril retards development of aortic valve stenosis in a rabbit model: mechanistic considerations: Ramipril retards development of aortic valve stenosis. British Journal of Pharmacology. 2011;162(3):722–32. DOI: 10.1111/j.1476-5381.2010.01084.xNgo DT, Stafford I, Sverdlov AL, Qi W, Wuttke RD, Zhang Y et al. Ramipril retards development of aortic valve stenosis in a rabbit model: mechanistic considerations: Ramipril retards development of aortic valve stenosis. British Journal of Pharmacology. 2011;162(3):722–32. DOI: 10.1111/j.1476-5381.2010.01084.xSimolin MA, Pedersen TX, Bro S, Mäyränpää MI, Helske S, Nielsen LB et al. ACE inhibition attenuates uremia-induced aortic valve thickening in a novel mouse model. BMC Cardiovascular Disorders. 2009;9(1):10. DOI: 10.1186/1471-2261-9-10Simolin MA, Pedersen TX, Bro S, Mäyränpää MI, Helske S, Nielsen LB et al. ACE inhibition attenuates uremia-induced aortic valve thickening in a novel mouse model. BMC Cardiovascular Disorders. 2009;9(1):10. DOI: 10.1186/1471-2261-9-10Bull S, Loudon M, Francis JM, Joseph J, Gerry S, Karamitsos TD et al. A prospective, double-blind, randomized controlled trial of the angiotensin-converting enzyme inhibitor Ramipril In Aortic Stenosis (RIAS trial). European Heart Journal – Cardiovascular Imaging. 2015;16(8):834–41. DOI: 10.1093/ehjci/jev043Bull S, Loudon M, Francis JM, Joseph J, Gerry S, Karamitsos TD et al. A prospective, double-blind, randomized controlled trial of the angiotensin-converting enzyme inhibitor Ramipril In Aortic Stenosis (RIAS trial). European Heart Journal – Cardiovascular Imaging. 2015;16(8):834–41. DOI: 10.1093/ehjci/jev043Chockalingam A, Venkatesan S, Subramaniam T, Jagannathan V, Elangovan S, Alagesan R et al. Safety and efficacy of angiotensin-converting enzyme inhibitors in symptomatic severe aortic stenosis: symptomatic cardiac obstruction–pilot study of enalapril in aortic stenosis (SCOPE-AS). American Heart Journal. 2004;147(4):740. DOI: 10.1016/j.ahj.2003.10.017Chockalingam A, Venkatesan S, Subramaniam T, Jagannathan V, Elangovan S, Alagesan R et al. Safety and efficacy of angiotensin-converting enzyme inhibitors in symptomatic severe aortic stenosis: symptomatic cardiac obstruction–pilot study of enalapril in aortic stenosis (SCOPE-AS). American Heart Journal. 2004;147(4):740. DOI: 10.1016/j.ahj.2003.10.017Dalsgaard M, Iversen K, Kjaergaard J, Grande P, Goetze JP, Clemmensen P et al. Short-term hemodynamic effect of angiotensin-converting enzyme inhibition in patients with severe aortic stenosis. American Heart Journal. 2014;167(2):226–34. DOI: 10.1016/j.ahj.2013.11.002Dalsgaard M, Iversen K, Kjaergaard J, Grande P, Goetze JP, Clemmensen P et al. Short-term hemodynamic effect of angiotensin-converting enzyme inhibition in patients with severe aortic stenosis. American Heart Journal. 2014;167(2):226–34. DOI: 10.1016/j.ahj.2013.11.002Capoulade R, Clavel M-A, Mathieu P, Côté N, Dumesnil JG, Arsenault M et al. Impact of hypertension and renin-angiotensin system inhibitors in aortic stenosis. European Journal of Clinical Investigation. 2013;43(12):1262–72. DOI: 10.1111/eci.12169Capoulade R, Clavel M-A, Mathieu P, Côté N, Dumesnil JG, Arsenault M et al. Impact of hypertension and renin-angiotensin system inhibitors in aortic stenosis. European Journal of Clinical Investigation. 2013;43(12):1262–72. DOI: 10.1111/eci.12169Côté N, Couture C, Pibarot P, Després J-P, Mathieu P. Angiotensin receptor blockers are associated with a lower remodelling score of stenotic aortic valves. European Journal of Clinical Investigation. 2011;41(11):1172–9. DOI: 10.1111/j.1365-2362.2011.02522.xCôté N, Couture C, Pibarot P, Després J-P, Mathieu P. Angiotensin receptor blockers are associated with a lower remodelling score of stenotic aortic valves. European Journal of Clinical Investigation. 2011;41(11):1172–9. DOI: 10.1111/j.1365-2362.2011.02522.xYamamoto K, Yamamoto H, Yoshida K, Kisanuki A, Hirano Y, Ohte N et al. Prognostic factors for progression of early- and late-stage calcific aortic valve disease in Japanese: The Japanese Aortic Stenosis Study (JASS) Retrospective Analysis. Hypertension Research. 2010;33(3):269–74. DOI: 10.1038/hr.2009.225Yamamoto K, Yamamoto H, Yoshida K, Kisanuki A, Hirano Y, Ohte N et al. Prognostic factors for progression of early- and late-stage calcific aortic valve disease in Japanese: The Japanese Aortic Stenosis Study (JASS) Retrospective Analysis. Hypertension Research. 2010;33(3):269–74. DOI: 10.1038/hr.2009.225Rosenhek R, Rader F, Loho N, Gabriel H, Heger M, Klaar U et al. Statins but Not Angiotensin-Converting Enzyme Inhibitors Delay Progression of Aortic Stenosis. Circulation. 2004;110(10):1291–5. DOI: 10.1161/01.CIR.0000140723.15274.53Rosenhek R, Rader F, Loho N, Gabriel H, Heger M, Klaar U et al. Statins but Not Angiotensin-Converting Enzyme Inhibitors Delay Progression of Aortic Stenosis. Circulation. 2004;110(10):1291–5. DOI: 10.1161/01.CIR.0000140723.15274.53O’Brien KD, Probstfield JL, Caulfield MT, Nasir K, Takasu J, Shavelle DM et al. Angiotensin-Converting Enzyme Inhibitors and Change in Aortic Valve Calcium. Archives of Internal Medicine. 2005;165(8):858–62. DOI: 10.1001/archinte.165.8.858O’Brien KD, Probstfield JL, Caulfield MT, Nasir K, Takasu J, Shavelle DM et al. Angiotensin-Converting Enzyme Inhibitors and Change in Aortic Valve Calcium. Archives of Internal Medicine. 2005;165(8):858–62. DOI: 10.1001/archinte.165.8.858Nadir MA, Wei L, Elder DHJ, Libianto R, Lim TK, Pauriah M et al. Impact of Renin-Angiotensin System Blockade Therapy on Outcome in Aortic Stenosis. Journal of the American College of Cardiology. 2011;58(6):570–6. DOI: 10.1016/j.jacc.2011.01.063Nadir MA, Wei L, Elder DHJ, Libianto R, Lim TK, Pauriah M et al. Impact of Renin-Angiotensin System Blockade Therapy on Outcome in Aortic Stenosis. Journal of the American College of Cardiology. 2011;58(6):570–6. DOI: 10.1016/j.jacc.2011.01.063Chen J-H, Simmons CA. Cell–Matrix Interactions in the Pathobiology of Calcific Aortic Valve Disease: Critical Roles for Matricellular, Matricrine, and Matrix Mechanics Cues. Circulation Research. 2011;108(12):1510–24. DOI: 10.1161/CIRCRESAHA.110.234237Chen J-H, Simmons CA. Cell–Matrix Interactions in the Pathobiology of Calcific Aortic Valve Disease: Critical Roles for Matricellular, Matricrine, and Matrix Mechanics Cues. Circulation Research. 2011;108(12):1510–24. DOI: 10.1161/CIRCRESAHA.110.234237Yip CYY, Simmons CA. The aortic valve microenvironment and its role in calcific aortic valve disease. Cardiovascular Pathology. 2011;20(3):177–82. DOI: 10.1016/j.carpath.2010.12.001Yip CYY, Simmons CA. The aortic valve microenvironment and its role in calcific aortic valve disease. Cardiovascular Pathology. 2011;20(3):177–82. DOI: 10.1016/j.carpath.2010.12.001Balachandran K, Sucosky P, Jo H, Yoganathan AP. Elevated Cyclic Stretch Induces Aortic Valve Calcification in a Bone Morphogenic ProteinDependent Manner. The American Journal of Pathology. 2010;177(1):49–57. DOI: 10.2353/ajpath.2010.090631Balachandran K, Sucosky P, Jo H, Yoganathan AP. Elevated Cyclic Stretch Induces Aortic Valve Calcification in a Bone Morphogenic ProteinDependent Manner. The American Journal of Pathology. 2010;177(1):49–57. DOI: 10.2353/ajpath.2010.090631Helske-Suihko S, Laine M, Lommi J, Kaartinen M, Werkkala K, Kovanen PT et al. Is Blockade of the Renin-angiotensin System Able to Reverse the Structural and Functional Remodeling of the Left Ventricle in Severe Aortic Stenosis? Journal of Cardiovascular Pharmacology. 2015;65(3):233–40. DOI: 10.1097/FJC.0000000000000182Helske-Suihko S, Laine M, Lommi J, Kaartinen M, Werkkala K, Kovanen PT et al. Is Blockade of the Renin-angiotensin System Able to Reverse the Structural and Functional Remodeling of the Left Ventricle in Severe Aortic Stenosis? Journal of Cardiovascular Pharmacology. 2015;65(3):233–40. DOI: 10.1097/FJC.0000000000000182Bang CN, Greve AM, Køber L, Rossebø AB, Ray S, Boman K et al. Renin–angiotensin system inhibition is not associated with increased sudden cardiac death, cardiovascular mortality or all-cause mortality in patients with aortic stenosis. International Journal of Cardiology. 2014;175(3):492–8. DOI: 10.1016/j.ijcard.2014.06.013Bang CN, Greve AM, Køber L, Rossebø AB, Ray S, Boman K et al. Renin–angiotensin system inhibition is not associated with increased sudden cardiac death, cardiovascular mortality or all-cause mortality in patients with aortic stenosis. International Journal of Cardiology. 2014;175(3):492–8. DOI: 10.1016/j.ijcard.2014.06.013Dell’Italia LJ, Collawn JF, Ferrario CM. Multifunctional Role of Chymase in Acute and Chronic Tissue Injury and Remodeling. Circulation Research. 2018;122(2):319–36. DOI: 10.1161/CIRCRESAHA.117.310978Dell’Italia LJ, Collawn JF, Ferrario CM. Multifunctional Role of Chymase in Acute and Chronic Tissue Injury and Remodeling. Circulation Research. 2018;122(2):319–36. DOI: 10.1161/CIRCRESAHA.117.310978Ahmad S, Ferrario CM. Chymase inhibitors for the treatment of cardiac diseases: a patent review (2010–2018). Expert Opinion on Therapeutic Patents. 2018;28(11):755–64. DOI: 10.1080/13543776.2018.1531848Ahmad S, Ferrario CM. Chymase inhibitors for the treatment of cardiac diseases: a patent review (2010–2018). Expert Opinion on Therapeutic Patents. 2018;28(11):755–64. DOI: 10.1080/13543776.2018.1531848Nguyen G, Muller DN. The Biology of the (Pro)Renin Receptor. Journal of the American Society of Nephrology. 2010;21(1):18–23. DOI: 10.1681/ASN.2009030300Nguyen G, Muller DN. The Biology of the (Pro)Renin Receptor. Journal of the American Society of Nephrology. 2010;21(1):18–23. DOI: 10.1681/ASN.2009030300Cruciat C-M, Ohkawara B, Acebron SP, Karaulanov E, Reinhard C, Ingelfinger D et al. Requirement of Prorenin Receptor and Vacuolar H+-ATPase-Mediated Acidification for Wnt Signaling. Science. 2010;327(5964):459–63. DOI: 10.1126/science.1179802Cruciat C-M, Ohkawara B, Acebron SP, Karaulanov E, Reinhard C, Ingelfinger D et al. Requirement of Prorenin Receptor and Vacuolar H+-ATPase-Mediated Acidification for Wnt Signaling. Science. 2010;327(5964):459–63. DOI: 10.1126/science.1179802

The authors declare that there are no conflicts of interest present.